(Q37864096)

24 August 2017

1 reference

title

Targeting tumour angiogenesis with small molecule inhibitors of hypoxia inducible factor (English)

1 reference

24 August 2017

0 references

1 reference

1 reference

Ida Karin Nordgren

1

1 reference

24 August 2017

Ali Tavassoli

series ordinal

2

1 reference

24 August 2017

publication date

11 April 2011

1 reference

24 August 2017

published in

Chemical Society Reviews

1 reference

24 August 2017

volume

40

1 reference

24 August 2017

issue

8

1 reference

24 August 2017

page(s)

4307-4317

1 reference

Targeting metabolic transformation for cancer therapy.

24 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1039%2FC1CS15032D

Hypoxia or in situ normoxia: The stem cell paradigm

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1CS15032D

Transcriptional regulation of vascular endothelial cell responses to hypoxia by HIF-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1CS15032D

Principles of Ligand Binding within a Completely Buried Cavity in HIF2α PAS-B

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1CS15032D

Structural basis for PAS domain heterodimerization in the basic helix-loop-helix-PAS transcription factor hypoxia-inducible factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1CS15032D

Structural basis of ARNT PAS-B dimerization: use of a common beta-sheet interface for hetero- and homodimerization

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1CS15032D

Artificial ligand binding within the HIF2 PAS-B domain of the HIF2 transcription factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1CS15032D

The human HIF (hypoxia-inducible factor)-3alpha gene is a HIF-1 target gene and may modulate hypoxic gene induction

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1CS15032D

Transcriptional up-regulation of inhibitory PAS domain protein gene expression by hypoxia-inducible factor 1 (HIF-1): a negative feedback regulatory circuit in HIF-1-mediated signaling in hypoxic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1CS15032D

Induction of hypoxia-inducible-factor 1 by nitric oxide is mediated via the PI 3K pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1CS15032D

Targeting the hypoxia-inducible factor (HIF) pathway in cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1CS15032D

Structural basis for recruitment of CBP/p300 by hypoxia-inducible factor-1 alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1CS15032D

Hypoxia inducible factor-2alpha in cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1CS15032D

HIF-1 regulation: not so easy come, easy go

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1CS15032D

Turn me on: regulating HIF transcriptional activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1CS15032D

Identification of MAPK phosphorylation sites and their role in the localization and activity of hypoxia-inducible factor-1alpha.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1CS15032D

HAF : the new player in oxygen-independent HIF-1alpha degradation

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1CS15032D

Development of HIF-1 inhibitors for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1CS15032D

Hypoxia-inducible factor-1 in human breast and prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1CS15032D

The HIF pathway in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1CS15032D

Regulation of cancer cell metabolism by hypoxia-inducible factor 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1CS15032D

Hypoxia and adaptive landscapes in the evolution of carcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1CS15032D

Hypoxia-inducible factors: central regulators of the tumor phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1CS15032D

The N-terminal transactivation domain confers target gene specificity of hypoxia-inducible factors HIF-1alpha and HIF-2alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1CS15032D

Evaluation of HIF-1 inhibitors as anticancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1CS15032D

Novel agents on the horizon for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1CS15032D

The Expression and Distribution of the Hypoxia-Inducible Factors HIF-1α and HIF-2α in Normal Human Tissues, Cancers, and Tumor-Associated Macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1CS15032D

Nitric oxide is a factor in the stabilization of hypoxia-inducible factor-1alpha in cancer: role of free radical formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1CS15032D

Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1CS15032D

Hypoxia-induced resistance to anticancer drugs is associated with decreased senescence and requires hypoxia-inducible factor-1 activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1CS15032D

Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1CS15032D

Dominant-negative hypoxia-inducible factor-1 alpha reduces tumorigenicity of pancreatic cancer cells through the suppression of glucose metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1CS15032D

HIF-1alpha and HIF-2alpha have divergent roles in colon cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1CS15032D

The contribution of VHL substrate binding and HIF1-alpha to the phenotype of VHL loss in renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1CS15032D

HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1alpha (HIF-1alpha) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1CS15032D

21 January 2018

The Hallmarks of Cancer

1 reference

https://api.crossref.org/works/10.1039%2FC1CS15032D

Abietane diterpenes from Salvia miltiorrhiza inhibit the activation of hypoxia-inducible factor-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1CS15032D

Identification of novel small molecule inhibitors of hypoxia-inducible factor-1 that differentially block hypoxia-inducible factor-1 activity and hypoxia-inducible factor-1alpha induction in response to hypoxic stress and growth factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1CS15032D

Echinomycin, a small-molecule inhibitor of hypoxia-inducible factor-1 DNA-binding activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1CS15032D

Acriflavine inhibits HIF-1 dimerization, tumor growth, and vascularization

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1CS15032D

Digoxin and other cardiac glycosides inhibit HIF-1alpha synthesis and block tumor growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1CS15032D

Everolimus (RAD001) and anti-angiogenic cyclophosphamide show long-term control of gastric cancer growth in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1CS15032D

Antiangiogenic potential of the Mammalian target of rapamycin inhibitor temsirolimus

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1CS15032D

CCI-779 inhibits rhabdomyosarcoma xenograft growth by an antiangiogenic mechanism linked to the targeting of mTOR/Hif-1alpha/VEGF signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1CS15032D

Inhibition of histone deacetylase down-regulates the expression of hypoxia-induced vascular endothelial growth factor by rheumatoid synovial fibroblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1CS15032D

Selective growth inhibition of tumor cells by a novel histone deacetylase inhibitor, NVP-LAQ824.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1CS15032D

Targeting heat shock protein 90 overrides the resistance of lung cancer cells by blocking radiation-induced stabilization of hypoxia-inducible factor-1alpha.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1CS15032D

Small-molecule activation of p53 blocks hypoxia-inducible factor 1alpha and vascular endothelial growth factor expression in vivo and leads to tumor cell apoptosis in normoxia and hypoxia

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1CS15032D

Anthracycline chemotherapy inhibits HIF-1 transcriptional activity and tumor-induced mobilization of circulating angiogenic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1CS15032D

Modulating hypoxia-inducible transcription by disrupting the HIF-1-DNA interface

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1CS15032D

Inhibition of transcription factors with small organic molecules

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1CS15032D

Molecular mechanisms for the activity of PX-478, an antitumor inhibitor of the hypoxia-inducible factor-1alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1CS15032D

Rapid degradation of hypoxia-inducible factor-1alpha by KRH102053, a new activator of prolyl hydroxylase 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1CS15032D

HIF-dependent antitumorigenic effect of antioxidants in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1CS15032D

The HIF pathway as a therapeutic target

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1CS15032D

Suppression of tumor growth through disruption of hypoxia-inducible transcription

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1CS15032D

Small molecule blockade of transcriptional coactivation of the hypoxia-inducible factor pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1CS15032D

RACK1 competes with HSP90 for binding to HIF-1alpha and is required for O(2)-independent and HSP90 inhibitor-induced degradation of HIF-1alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1CS15032D

Targeting the PAS-A domain of HIF-1alpha for development of small molecule inhibitors of HIF-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1CS15032D

A novel mode of action of YC-1 in HIF inhibition: stimulation of FIH-dependent p300 dissociation from HIF-1{alpha}.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1CS15032D

Targeting HIF-1 for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1CS15032D

Activation of the aryl hydrocarbon receptor by structurally diverse exogenous and endogenous chemicals

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1CS15032D

Recruitment of HIF-1α and HIF-2α to common target genes is differentially regulated in neuroblastoma: HIF-2α promotes an aggressive phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1CS15032D

21 January 2018

Identifiers

DOI

10.1039/C1CS15032D

1 reference

24 August 2017

1 reference